PainChek

PainChek Rule of 40

The Rule of 40 of PainChek (PCK.AX) as of Nov 20, 2026 is -253.68 %. In the previous year, Rule of 40 was -245.15 % — a change of 3.48% (lower).

Rule of 40

-253.68 %

YoY

3.48%

Last updated:

Rule of 40 of PainChek is 2026 -253.68 % . Rule of 40 of PainChek was 2025 -245.15 % . It decreases by 3.48% lower compared to the previous year.

The PainChek Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
-1,188.71 AUD
Jan 1, 2020
-6,044.78 AUD
Jan 1, 2021
-4,189.16 AUD
Jan 1, 2022
-419.99 AUD
Jan 1, 2023
-350.22 AUD
Jan 1, 2024
-319.02 AUD
Jan 1, 2025
-245.15 AUD
Jan 1, 2026
-253.68 AUD
The PainChek Rule of 40 history
YEARRule of 40YoY
-253.68 %+3.48%
-245.15 %-23.16%
-319.02 %-8.91%
-350.22 %-16.61%
-419.99 %-89.97%
-4,189.16 %-30.70%
-6,044.78 %+408.51%
-1,188.71 %-87.40%
-9,435.39 %-22.48%
-12,171.99 %-63.58%
-33,416.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PainChek Stock analysis

What does PainChek do? PainChek Ltd. develops and commercializes mobile medical device applications, focusing on pain assessment for individuals unable to communicate with carers. The PainChek Universal combines the PainChek Application with the numerical rating scale (NRS), using artificial intelligence and facial recognition to detect pain in non-verbal patients. It provides a point-of-care solution that offers objectivity and consistency in pain assessments, supporting both non-verbal and self-reporting individuals through integrated tools. Healthcare providers and care facilities purchase PainChek Universal to enhance pain management protocols for patients with communication difficulties. The PainChek Application utilizes artificial intelligence and facial recognition technology to assess pain without relying on patient self-reporting, making it suitable for those with cognitive or physical impairments. PainChek Universal integrates the NRS for patients who can self-report, ensuring a comprehensive approach to pain evaluation across varying patient capabilities. This dual functionality allows healthcare professionals to apply consistent assessment standards regardless of a patient's ability to communicate. PainChek Ltd. generates revenue through the commercialization of its mobile medical device applications, specifically targeting healthcare providers and care facilities that require standardized pain assessment tools. The company’s products are designed to address the needs of patients who cannot communicate pain, thereby filling a critical gap in healthcare services. By offering a unified solution that combines AI-driven detection with traditional rating scales, PainChek Universal meets the demands of modern healthcare environments seeking objective and reliable pain management solutions. PainChek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PainChek stock

Rule of 40 of PainChek is -253.68 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 PainChek since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — PainChek

All Key Metrics — PainChek